Association between perioperative low-molecular-weight heparin vs unfractionated heparin and clinical outcomes in patients with cancer undergoing surgery
- PMID: 25849181
- DOI: 10.1001/jama.2015.498
Association between perioperative low-molecular-weight heparin vs unfractionated heparin and clinical outcomes in patients with cancer undergoing surgery
Abstract
Clinical question: In patients with cancer undergoing surgery, what is the association between perioperative thromboprophylaxis with low-molecular-weight heparin (LMWH) or unfractionated heparin and mortality, pulmonary embolism, deep venous thrombosis, thrombocytopenia, and bleeding outcomes?
Bottom line: When used for perioperative thromboprophylaxis, there are no differences in the association of LMWH vs unfractionated heparin for preventing mortality, pulmonary embolism, deep venous thrombosis, bleeding outcomes, or thrombocytopenia in patients with cancer.
Comment on
-
Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer.Cochrane Database Syst Rev. 2014 Jun 26;(6):CD009447. doi: 10.1002/14651858.CD009447.pub2. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2018 Jul 11;7:CD009447. doi: 10.1002/14651858.CD009447.pub3. PMID: 24966161 Updated.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical